0001209191-23-042454.txt : 20230717 0001209191-23-042454.hdr.sgml : 20230717 20230717170014 ACCESSION NUMBER: 0001209191-23-042454 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230714 FILED AS OF DATE: 20230717 DATE AS OF CHANGE: 20230717 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Curran Terrie CENTRAL INDEX KEY: 0001690298 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39094 FILM NUMBER: 231092218 MAIL ADDRESS: STREET 1: C/O MYOVANT SCIENCES INC. STREET 2: 320 WEST 37TH STREET, 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001783183 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824151574 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (877) 742-8466 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-07-14 0 0001783183 Phathom Pharmaceuticals, Inc. PHAT 0001690298 Curran Terrie C/O PHATHOM PHARMACEUTICALS, INC. 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 1 1 0 0 President and Chief Executive 0 Common Stock 2023-07-14 4 A 0 200000 A 389671 D Common Stock 3579.61 I by 401(k) Stock Option 32.20 2023-07-14 4 D 0 175000 D 2030-06-30 Common Stock 175000 0 D Stock Option 39.11 2023-07-14 4 D 0 225000 D 2031-01-27 Common Stock 225000 0 D On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. Includes 1,381 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023. Includes 1,223.71 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan. /s/ Larry Miller, Attorney-in-Fact for Terrie Curran 2023-07-17